Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VERVE-201 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 2: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 3: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 4: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 5: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Cohort 6: Single Ascending Dose Escalation | EXPERIMENTAL | Participants will receive a single dose of VERVE-201. |
| Name | Type | Description |
|---|---|---|
| VERVE-201 | DRUG | Intravenous (IV) infusion |
Inclusion Criteria: * Refractory hypercholesterolemia * Refractory hypertriglyceridemia Exclusion Criteria: * Active or history of chronic liver disease * Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe * Clinically significant or abnorma...
VERVE-201 is an investigational small molecule being developed for hypercholesterolemia, a condition of high cholesterol. It is also being studied in patients with refractory hyperlipidemia, which includes hypercholesterolemia and hypertriglyceridemia. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
VERVE-201 targets ANGPTL3, a protein involved in lipid metabolism. By targeting ANGPTL3, the drug aims to address hypercholesterolemia and related lipid disorders. The drug is a small molecule, and its mechanism of action is centered on this molecular target.
VERVE-201 is being developed by Verve Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol VERV. Verve Therapeutics is conducting clinical trials to evaluate the safety and efficacy of VERVE-201 in patients with hyperlipidemia.
VERVE-201 is in Phase 1 clinical development. It is currently being studied in a Phase 1b trial for patients with refractory hyperlipidemia. The drug is investigational and has not been approved by the FDA or other regulatory agencies. The trial is actively recruiting participants.
VERVE-201 is being evaluated in a Phase 1b clinical trial with the identifier NCT06451770. This study is recruiting patients with refractory hyperlipidemia, including hypercholesterolemia and hypertriglyceridemia. The trial is enrolling 36 participants across multiple countries, including the United States, Australia, Canada, Netherlands, South Africa, and the United Kingdom.
VERVE-201 is the sole name provided for this investigational drug. No alternative names have been mentioned in the available information. It is a distinct small molecule being developed by Verve Therapeutics for the treatment of hypercholesterolemia and related lipid disorders.